The latest news from ANEUVO
The latest news from ANEUVO
Dr. Rebecca Martin, the Principal Investigator for ANEUVO's ASPIRE™ discusses TSS in SCI therapy.
Recently Dr. Rebecca Martin, the Principal Investigator for ANEUVO's ASPIRE™ clinical trial taking place at the Kennedy Krieger Institute, joined Liz Franzel from the Denver, CO based Crawford Media Group to discuss the role of Transcutaneous Spinal Stimulation (TSS) in SCI therapy.
Fox 7 News: Teen with cerebral palsy defying odds
For most people with cerebral palsy, it's a disease that, year after year, robs them of their independence. But 14-year-old Martin has defied those expectations, thanks partly to new spinal stimulation technology at the University of St. Augustine. Martin was the first to be enrolled in a pilot study this year using ExaStim.
Unite 2 Fight Paralysis CureCast Podcast
Dr. Yi-Kai Lo, CEO and Co-Founder, and Katie Velez, VP of Global Marketing and Strategy, had the opportunity to speak with Matthew Rodreick, U2FP Executive Director, and Jason Stoffer, CureCast Host, on Episode 87 of the Unite 2 Fight Paralysis CureCast podcast.
The 62nd International Spinal Cord Society Annual Scientific Meeting
ANEUVO was honored to host a breakfast symposium at the 62nd International Spinal Cord Society Annual Scientific Meeting in Edinburgh, Scotland. The symposium featured Drs. Yi-Kai Lo, Monica Perez, and Rebecca Martin.
Unite 2 Fight Paralysis Annual Symposium 2023
ANEUVO was excited to be the Networking Sponsor for the 2023 Unite 2 Fight Paralysis (U2FP) Annual Science and Advocacy Symposium which took place October 20-21, 2023 in Minneapolis, MN.
ISCoS Episode on SCI Care: What Really Matters
In this episode of ‘SCI Care: What Really Matters’ we focus on sharing information on the technological innovations in our field with a discussion about transcutaneous spinal stimulation (TSS).
Transformative Therapies for Chronic Spinal Cord Injury: The Role of Transcutaneous Spinal Stimulation in SCI Care.
Marquette ASPIRE Trial: 'ExaStim' paralysis device changing lives
For more than a decade, a Hartford woman grew to accept her limitations. A crash damaged her spinal cord, leaving her paralyzed from the chest down, but a new clinical trial is helping her regain her sense of freedom.
ANEUVO Launches US Study of ExaStim, a Non-invasive Spinal Neuromodulation System to Evaluate its Safety and Effectiveness for Paralysis due to Spinal Cord Injury
The ASPIRE clinical study is designed to demonstrate the safety and efficacy of the ExaStim® TSS system using non-invasive spinal cord stimulation to improve/regain the motor function of individuals with SCI. A maximum of 140 patients will be enrolled at up to 14 sites in the U.S.
ANEUVO is a Contributing Partner of NASCIC
NASCIC brings together like-minded organizations, individuals, and groups to improve research, care, cure, and policies impacting people living with spinal cord injury, their families, and the community.
ANEUVO CEO Yi-Kai Lo to Present at Unite 2 Fight for Paralysis
The symposium is “a collaborative gathering that prioritizes the voice of the Spinal Cord Injury (SCI) Community, bringing together research scientists, clinicians, and community advocates, along with investors and industry leaders to exchange information and strategies for achieving recovery from SCI.” The event takes place Thursday, October 21, through Saturday, October 23, 2021.
ANEUVO Awarded $999,999 from the National Science Foundation
ANEUVO* today announced that it has been recently awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $999,999 to conduct research and development work on an ingestible bioelectronic capsule for closed-loop diagnosis and treatment of gastrointestinal (GI) disorders. With this grant, ANEUVO will advance its novel GI technology development toward pre-clinical validation.
We are now ANEUVO.
Niche Biomedical is rebranding in preparation for continued growth and success! The name reflects new approaches to treatment, neural technology, and neural therapies and sets us apart as we begin moving toward future clinical trials and, ultimately, commercialization. We appreciate your support, encouragement, and attention since the formation of Niche Biomedical in 2016. We look forward to bringing innovative and effective medical solutions to help patients in need.